Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter

MT Newswires Live

2025/10/31

Race Oncology (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.

It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.

It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.

Its shares fell 2% in recent trading on Friday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579848629"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579848629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579848629?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579848629","market":"sg","top_or_hot":-1,"title":"Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.</p><p>It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.</p><p>It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.</p><p>Its shares fell 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-31 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.</p><p>It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.</p><p>It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.</p><p>Its shares fell 2% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAC.AU","symbol_name":"RACE ONCOLOGY LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579848629","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579848629","pubTimestamp":1761875382,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAC.AU":"RACE ONCOLOGY LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Race Oncology高级一期心脏保护、抗癌候选药物临床试验将于9月季度进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Race Oncology (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}